Sponsorship, authorship, and accountability.

@article{Davidoff2001SponsorshipAA,
  title={Sponsorship, authorship, and accountability.},
  author={Frank Davidoff and Catherine D Deangelis and Jeffrey M. Drazen and John R. Hoey and L H{\o}jgaard and Richard C. Horton and Sheldon Kotzin and M Gary Nicholls and Magne Nylenna and A. John P. M. Overbeke and Harold C. Sox and Martin B. van der Weyden and Michael S. Wilkes},
  journal={Obstetrics and gynecology},
  year={2001},
  volume={98 6},
  pages={
          1143-6
        }
}
AS EDITORS OF GENERAL MEDICAL JOURNALS, WE RECognize that the publication of clinical research findings in respected peer-reviewed journals is the ultimate basis for most treatment decisions. Public discourse about this published evidence of efficacy and safety rests on the assumption that clinical trials data have been gathered and are presented in an objective and dispassionate manner. This discourse is vital to the scientific practice of medicine because it shapes treatment decisions made by… 

Industry-sponsored clinical trials and medical publishing

  • N. Snell
  • Medicine
    International Journal of Pharmaceutical Medicine
  • 2012
A well-considered rebuttal and repays reading of the ICMJE attack on the integrity of the pharmaceutical industry, which gives the impression that only academic investigators have the expertise to design and interpret clinical trials, and the integrity to publish the findings.

Reporting Clinical Trials

Full disclosure of financial interests by authors is essential to retain public trust in biomedical research, the peer-review process and the integrity of the authors and of the universities.

Reporting Clinical Trials: Full Access to All the Data

  • L. Wilkins
  • Medicine
    Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
  • 2002
Full disclosure of financial interests by authors is essential to retain public trust in biomedical research, the peer-review process and the integrity of the authors and of the universities.

Framing the forum: medical ethics in large-scale, interventional respiratory clinical trials.

  • G. Criner
  • Medicine, Psychology
    Proceedings of the American Thoracic Society
  • 2007
This overview of ethics in clinical research will discuss some of the key contentious issues: informed consent (including payment for participation in a clinical trial, use of a placebo, and defining "standard of care"), research in critically ill patients, dissemination of study results, race issues, and financial disclosure.

Large Clinical Trials

Reporting clinical trials: full access to all the data.

Full disclosure of financial interests by authors is essential to retain public trust in biomedical research, the peer‐review process and the integrity of the authors and of the universities.

Framing the Forum

This overview of ethics in clinical research will discuss some of the key contentious issues: informed consent, informed consent (including payment for participation in a clinical trial, use of a placebo, and defining “standard of care”), research in critically ill patients, dissemination of study results, race issues, and financial disclosure.

Reporting clinical trials: full access to all the data.

Full disclosure of financial interests by authors is essential to retain public trust in biomedical research, the peer-review process, and the integrity of the authors and universities.

A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors.

Academic institutions routinely engage in industry-sponsored research that fails to adhere to ICMJE guidelines regarding trial design, access to data, and publication rights, and suggest that a reevaluation of the process of contracting for clinical research is urgently needed.

Ethical considerations in the interpretation and communication of clinical trial results.

  • D. Coultas
  • Medicine
    Proceedings of the American Thoracic Society
  • 2007
The objective of this article is to raise awareness among the pulmonary research community of the broad range of ethical issues that arise during manuscript preparation, review, publication, and dissemination of research results, and efforts that are in progress to minimize misconduct.
...

References

SHOWING 1-8 OF 8 REFERENCES

Withholding research results in academic life science. Evidence from a national survey of faculty.

Withholding of research results is not a widespread phenomenon among life-science researchers, however, withholding is more common among the most productive and entrepreneurial faculty.

Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial.

HIV-1 Immunogen with unrestricted ART failed to demonstrate an increase in HIV progression-free survival, as measured by overall survival, changes in HIV RNA, CD4 cell counts,CD4 percentage, body weight, and immunogenicity.

Parexel’s Pharmaceutical R&D Sourcebook

  • Parexel International Corp;
  • 1998

Thyroid storm. JAMA

  • 1997

other medical schools aim to give drug firms faster pace for trials

  • Boston Globe
  • 2000

More AMCs finding growth from reform

  • CenterWatch Newsletter
  • 2000

Harvard , other medical schools aim to give drug firms faster pace for trials

  • Boston Globe
  • 2000

Medical schools join forces: Harvard, others aim to give drug firms faster OK’s on clinical trials

  • Boston Globe. July
  • 2000